Tag: PFE

Finance

Investor’s Alert: American International Group Inc (NYSE:AIG), General Electric Company (NYSE:GE), Petroleo Brasileiro Petrobras (NYSE:PBR), Pfizer Inc. (NYSE:PFE)

American International Group Inc (NYSE:AIG) retreated 4.1 percent after the company reported a drop in its first-quarter operating income due to rising claims costs. American International Group Inc (NYSE:AIG) stock performance was -4.14% in last session and finished the day at $50.54. Traded volume was 21.78million shares in the last session and the average volume of the stock remained 9.33million shares. The beta of the … Continue reading Investor’s Alert: American International Group Inc (NYSE:AIG), General Electric Company (NYSE:GE), Petroleo Brasileiro Petrobras (NYSE:PBR), Pfizer Inc. (NYSE:PFE)

Jason Knox
BioTech

Biotech Pre-Market Movers: Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA), Synergy Pharmaceuticals Inc(NASDAQ:SGYP), Pfizer Inc.(NYSE:PFE), AstraZeneca plc (ADR)(NYSE:AZN)

The American Despositary Receipts of Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA) edged up in recent pre-market trading on Monday after announcing over the weekend an agreement it has signed with Takeda Pharmaceutical for the marketing and sale of Rasagiline in Japan. Rasagiline is a treatment for Parkinson’s Disease developed by TEVA and has been approved in over 40 countries. TEVA closed at $48.69 on Friday in … Continue reading Biotech Pre-Market Movers: Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA), Synergy Pharmaceuticals Inc(NASDAQ:SGYP), Pfizer Inc.(NYSE:PFE), AstraZeneca plc (ADR)(NYSE:AZN)

Ryan Holtz
BioTech, Stock Movers

AstraZeneca plc (ADR)(NYSE:AZN) Shares Soar Pre-Market

Shares of AstraZeneca plc (ADR)(NYSE:AZN) reached a new high in pre-market trading as Pfizer Inc.(NYSE:PFE) confirmed it has attempted to renew negotiations on a possible merger. Pfizer submitted a preliminary indication of interest to the board of directors of AstraZeneca in January 2014 regarding the possible merger. AstraZeneca declined to pursue negotiations at that time, but Pfizer contacted AstraZeneca on April 26, 2014, seeking to renew … Continue reading AstraZeneca plc (ADR)(NYSE:AZN) Shares Soar Pre-Market

Chris Lewis
FB Nasdaq FB Facebook
Finance

Healthcare Most Active Stocks: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Johnson & Johnson (NYSE:JNJ)

A proxy advisory firm has asked shareholders of the Indian unit of Wyeth to oppose its merger deal with Pfizer Inc. (NYSE:PFE) as the share swap ratio is skewed in favour of Pfizer Inc. (NYSE:PFE). Shareholder Empowerment Services (SES) has made this suggestion ahead of the shareholder meeting this week. Pfizer Inc. (NYSE:PFE) stock performance was 0.07% in last session and finished the day at … Continue reading Healthcare Most Active Stocks: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Johnson & Johnson (NYSE:JNJ)

Kristen Barton
Finance

Healthcare Active Runners: Gilead Sciences (NASDAQ:GILD), Pfizer Inc. (NYSE:PFE), Merck & Co. (NYSE:MRK), MannKind Corporation (NASDAQ:MNKD)

Gilead Sciences, Inc. (NASDAQ:GILD) announced data from two Phase 2 studies and a compassionate access study in which a regimen containing once-daily Sovaldi(R) (sofosbuvir) 400 mg was administered for the treatment of chronic hepatitis C virus (HCV) infection in patients with advanced liver disease. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was -7.32% in last session and finished the day at $65.48. Traded volume was 43.15million … Continue reading Healthcare Active Runners: Gilead Sciences (NASDAQ:GILD), Pfizer Inc. (NYSE:PFE), Merck & Co. (NYSE:MRK), MannKind Corporation (NASDAQ:MNKD)

Colin Pettis1 Comment
Finance

Healthcare Most Active Stocks: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Teva Pharmaceutical Industries (NYSE:TEVA), Bristol-Myers Squibb (NYSE:BMY)

During the trial, palbociclib — a pill — was combined with the standard anti-estrogen treatment Letrozole. The combined treatment resulted in a 26.1 month progression-free survival rate compared with only 7.5 months for Letrozole alone. Under development by Pfizer Inc. (NYSE:PFE), the medication used in the study is a selective inhibitor of cyclin-dependent kinases (CDK) 4 and 6. Pfizer Inc. (NYSE:PFE) stock performance was -1.06% … Continue reading Healthcare Most Active Stocks: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Teva Pharmaceutical Industries (NYSE:TEVA), Bristol-Myers Squibb (NYSE:BMY)

Jayne Crisman